Saturday, August 30, 2025 8/30/2025

Post-translational Regulation of Inducible cAMP Early Repressor and its Implications in Cancer

Award Number: SC1GM125583
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2018
PERIOD OF PERFORMANCE END DATE: 04/30/2023

Group Awards By:

View Award Description

Post-translational Regulation of Inducible cAMP Early Repressor and its Implications in Cancer - Project Summary/Abstract Even though Inducible cAMP Early Repressor (ICER) has the functional characteristics of a tumor suppressor, there is no genetic evidence to demonstrate that ICER is a bona fide tumor suppressor gene product. Thus, altered post-translational events might be the cause of the observed abnormalities of ICER protein expression in cancer cells. On this basis it is hypothesized that in cancer cells, ICER is deregulated by ubiquitination resulting in constitutive proteasomal degradation and/or abnormal subcellular localization. Finding alternatives to rescue endogenous ICER nuclear expression in malignant cells could lead to the development of novel cancer treatment modalities. Through this project, we will study the mechanisms and physiological consequences of ICER ubiquitination and subcellular localization. We will use melanoma as a paradigm for the study. This study will focus on two specific aims. Aim 1. Determine the functional and physiological consequences of ICER ubiquitination by characterizing the specific ubiquitination sites on ICER and ubiquitin E3 ligases using biochemistry, chromatin binding, and siRNA techniques. Aim 2. Examine the effect on tumorgenesis upon expression of “ubiquitinatable”-deficient ICER using mouse xenograft models and an established zebrafish model for melanoma. The overarching goal of this project is to determine the functional consequences of ICER post- translational modifications in cancer. The experiments described in this proposal will provide the basis for more extensive analyses of multi-component complexes associated with the regulation of ICER in cancer cells. Subsequent research will: 1) Use the zebrafish melanoma model to further characterize the molecular mechanisms of ICER ubiquitination during melanoma genesis; 2) Establish collaborative efforts to develop small-molecule compounds and small ICER-related peptides as specifics Ub-ligases inhibitors to test specific approaches to restore endogenous ICER nuclear expression in cancer cells; and 3) Study the effect of these Ub-ligase inhibitors in animal models for cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	MONTCLAIR STATE UNIVERSITY	1 NORMAL AVE	MONTCLAIR	NJ	07043	ESSEX	USA	Biomedical Research and Research Training	000	4	12/6/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $321,219 )
2021	2021	MONTCLAIR STATE UNIVERSITY	1 NORMAL AVE	MONTCLAIR	NJ	07043	ESSEX	USA	Biomedical Research and Research Training	000	4	4/13/2021	NON-COMPETING CONTINUATION	$321,219
														Subtotal = $321,219

Issue Date FY: 2020 ( Subtotal = $321,219 )
2020	2020	MONTCLAIR STATE UNIVERSITY	1 NORMAL AVE	MONTCLAIR	NJ	07043	ESSEX	USA	Biomedical Research and Research Training	000	3	4/17/2020	NON-COMPETING CONTINUATION	$321,219
														Subtotal = $321,219

Issue Date FY: 2019 ( Subtotal = $321,219 )
2019	2019	MONTCLAIR STATE UNIVERSITY	1 NORMAL AVE	MONTCLAIR	NJ	07043	ESSEX	USA	Biomedical Research and Research Training	000	2	4/29/2019	NON-COMPETING CONTINUATION	$321,219
														Subtotal = $321,219

Issue Date FY: 2018 ( Subtotal = $321,219 )
2018	2018	MONTCLAIR STATE UNIVERSITY	1 NORMAL AVE	MONTCLAIR	NJ	07043	ESSEX	USA	Biomedical Research and Research Training	000	1	4/27/2018	NEW	$321,219
														Subtotal = $321,219

Grand Total All Awards = $1,284,876

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Post-translational Regulation of Inducible cAMP Early Repressor and its Implications in Cancer

Award Number: SC1GM125583

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2018

PERIOD OF PERFORMANCE END DATE: 04/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer